Today's top story Pfizer and GSK pooling up for AIDS and HIV drugs, In this new venture GSk will have 85% stake and Pfizer 15% and will have 11 marketed drugs in its goodie bag including GSK top-sellers Combivir and Epzicom which together generated sales of 1.6 billion pounds ($2.4 billion) in 2008, it also includes six new medicines, of which four are in mid of Phase II development.
this risk sharing partnership will foster pfizer's new drug such as Selzentry entry while filling up GSK older patent portfolio and later pfizer's benefit's from GSK overall global HIV/AIDS market distribution.
The new company will hold nearly fifth of market against HIV/AIDS treatment. This is a clear threat to Gilead which should rather focus in new development and expansion of it's HIV/AIDS portfolio in future to maintain its present market cap of $40 billion.
Today Gilead's profit pills combined sales in $4 Billion but Gilead should straterzise its future in a careful way to upbeat the new alliance.
